David Sidransky
Founder chez CHAMPIONS ONCOLOGY, INC.
Fortune : 4 M $ au 31/03/2024
Profil
David Sidransky is the founder of Champions Oncology, Inc. (founded in 2008) and Israel Biotech Fund (founded in 2014), where he holds the titles of Lead Director and General Partner, respectively.
He currently holds the position of Chairman at Old Ayala, Inc. (since 2019), Biosight Therapeutics, Inc. (since 2013), Ayala Pharmaceuticals, Inc. (since 2017), Rosetta Genomics Ltd.
(since 2009), Orgenesis, Inc. (since 2013), The Sidney Kimmel Comprehensive Cancer Center (since 1994), Immune Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd.
(since 2014), Ascentage Pharma Group International Co., Ltd.
(since 2021), Biond Biologics Ltd., Exoprother Medical, The Johns Hopkins University (since 1998), American Society of Clinical Oncology, Inc., Biomerk, Inc., The Johns Hopkins University School of Medicine, and The American Association of Cancer Research.
He has also held former positions as Chairman of Tamir Biotechnology, Inc. (2007-2020), Vice Chairman of ImClone LLC (2004-2008), Chairman of Old Ayala, Inc. (2017-2023), Independent Director of AMAG Pharma USA, Inc. (2012-2013), Director of AMAG Pharma USA, Inc. (2010-2012), Director of Zila, Inc. (2006-2007), Board of Director of Celsus Therapeutics Plc (2012-2015), Director of Advaxis, Inc. (2013-2015), Director of American Association for Cancer Research (2005-2008), Director of National Institute of Dental & Craniofacial Research, Director of Efranat Ltd., Director of Akari Therapeutics Plc, Director of Cardiff Oncology, Inc., Independent Director of Cactus Acquisition Corp.
1 Ltd., and Senior Editor of Clinical Cancer Research (2005-2008).
Dr. Sidransky obtained his undergraduate degree from Brandeis University in 1981 and his doctorate degree from Baylor College of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CHAMPIONS ONCOLOGY, INC.
5,64% | 03/11/2023 | 767 043 ( 5,64% ) | 4 M $ | 31/03/2024 |
| 27/03/2024 | 500 ( 0,01% ) | 173 $ | 31/03/2024 | |
| 12/12/2022 | 93 ( 0,00% ) | 60 $ | 31/03/2024 | |
ORGENESIS INC.
-.--% | 20/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de David Sidransky
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Director/Board Member | 26/08/2013 |
| ORGENESIS INC. | Director/Board Member | 18/07/2013 |
| CHAMPIONS ONCOLOGY, INC. | Founder | 01/01/2008 |
| ROSETTA GENOMICS LTD. | Director/Board Member | 22/12/2009 |
| GALMED PHARMACEUTICALS LTD. | Director/Board Member | 01/06/2014 |
| ADVAXIS, INC. | Chairman | 01/05/2019 |
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Director/Board Member | 31/03/2021 |
| AYALA PHARMACEUTICALS, INC. | Chairman | 01/11/2017 |
| The Johns Hopkins University School of Medicine | Corporate Officer/Principal | 01/01/1994 |
| ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░░░░░░ ░░░░░░░░░░░ ░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Anciens postes connus de David Sidransky
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░ ░░░░░ ░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de David Sidransky
| Brandeis University | Undergraduate Degree |
| Baylor College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 9 |
|---|---|
| ROSETTA GENOMICS LTD. | Health Technology |
| ORGENESIS INC. | Health Technology |
| CARDIFF ONCOLOGY, INC. | Health Technology |
| CHAMPIONS ONCOLOGY, INC. | Health Technology |
| GALMED PHARMACEUTICALS LTD. | Health Technology |
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Health Technology |
| AKARI THERAPEUTICS, PLC | Health Technology |
| CACTUS ACQUISITION CORP. 1 LIMITED | Finance |
| AYALA PHARMACEUTICALS, INC. | Commercial Services |
| Entreprise privées | 19 |
|---|---|
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
AMAG Pharma USA, Inc.
 AMAG Pharma USA, Inc. Pharmaceuticals: MajorHealth Technology AMAG PHARMA USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA. | Health Technology |
Zila, Inc.
 Zila, Inc. Medical SpecialtiesHealth Technology Zila, Inc., headquartered in Scottsdale, Arizona and founded in 1988, is a diagnostic company that offers prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite Plus with TBlue (“ViziLite Plus”), the company’s product for the detection of oral abnormalities that could lead to cancer. ViziLite Plus is a medical device for use in a popilation risking for oral cancer. Zila designs, manufactures and markets products sold directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler and oral pharmaceutical products for both in-office and home-care use | Health Technology |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
| Clinical Cancer Research | |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
Biomerk, Inc.
 Biomerk, Inc. Medical/Nursing ServicesHealth Services Part of Champions Oncology, Inc., Biomerk, Inc. is a private company that owns and operates medical research laboratories. The company is based in Scottsdale, AZ. Biomerk was acquired by Champions Oncology, Inc. on May 18, 2007 for $1.16 million. | Health Services |
The Sidney Kimmel Comprehensive Cancer Center
 The Sidney Kimmel Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD. | Health Services |
| National Institute of Dental & Craniofacial Research | Government |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Efranat Ltd.
 Efranat Ltd. Pharmaceuticals: MajorHealth Technology Efranat Ltd. develops anti-cancer immunotherapy treatment. Its product is based on a natural plasma glycoprotein molecule that activates the innate immune system against cancer. The company was founded by Boaz Shoham, Nobuto Yamamoto and Avi Levin in 2009 and is headquartered in Rehovot, Israel. | Health Technology |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Biond Biologics Ltd.
 Biond Biologics Ltd. Pharmaceuticals: MajorHealth Technology Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. | Health Technology |
Old Ayala, Inc.
 Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
| The American Association of Cancer Research | |
Exoprother Medical
 Exoprother Medical Hospital/Nursing ManagementHealth Services Exoprother Medical is an Israeli company that focuses on developing a cancer treatment inspired by evolution. The company is based in Yokne'am Illit, Israel. The company targets the p53 based tumor suppression mechanism that is mutated in over 60%% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. The company uses exosomes, natural nano-particles produced by most living cells, to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side-effects. Exoprother Medical was founded by Lana Volokh and Alex Tendler, and Lana Volokh has been the CEO since incorporation. | Health Services |
